![\"Femeia](\"https:\/\/www.europesays.com\/ro\/wp-content\/uploads\/2026\/04\/1775932087_779_index.jpeg\")
<\/p>\nO femeie care s-a confruntat timp de peste un deceniu cu trei boli autoimune grave, care \u00eei puneau via\u021ba \u00een pericol, a reu\u0219it s\u0103 revin\u0103 la o via\u021b\u0103 aproape normal\u0103, dup\u0103 ce o terapie celular\u0103 i-a resetat sistemul imunitar afectat.<\/p>\n
\t\t\t<\/p>\n
Femeia a urmat un tratament revolu\u021bionar FOTO Unplash<\/p>\n
publicitate”); background-position: center center; background-repeat: no-repeat;”><\/p>\n
Pacienta, \u00een v\u00e2rst\u0103 de 47 de ani, urmase anterior nou\u0103 tratamente diferite, f\u0103r\u0103 efecte de durat\u0103, \u00eenainte de a primi terapia anul trecut, la un spital universitar din Germania. La acel moment, avea nevoie zilnic de transfuzii de s\u00e2nge \u0219i de tratament anticoagulant administrat permanent pentru a-\u0219i \u021bine boala sub control, scrie The Guardian.<\/a><\/p>\n La doar c\u00e2teva s\u0103pt\u0103m\u00e2ni dup\u0103 administrarea terapiei, medicii au observat c\u0103 toate cele trei afec\u021biuni au r\u0103spuns tratamentului \u2013 o premier\u0103 la nivel mondial \u0219i o \u00eembun\u0103t\u0103\u021bire spectaculoas\u0103 a st\u0103rii pacientei. De 14 luni, aceasta se afl\u0103 \u00een remisie f\u0103r\u0103 tratament \u0219i a reu\u0219it, \u00een mare parte, s\u0103 revin\u0103 la o via\u021b\u0103 normal\u0103.<\/p>\n Coordonatorul echipei medicale a descris reac\u021bia drept \u201eremarcabil\u0103\u201d, subliniind c\u0103 terapia i-a \u00eembun\u0103t\u0103\u021bit semnificativ calitatea vie\u021bii. Totu\u0219i, sunt necesare studii clinice pentru a evalua c\u00e2t de durabile sunt efectele \u0219i dac\u0103 metoda poate fi aplicat\u0103 \u0219i \u00een alte boli autoimune, mai noteaz\u0103 publica\u021bia.<\/p>\n \t\t\tF\u0103r\u0103 op\u021biuni de tratament<\/p>\n Femeia suferea de o afec\u021biune rar\u0103 \u0219i grav\u0103 a s\u00e2ngelui \u2013 anemie hemolitic\u0103 autoimun\u0103 (AIHA) \u2013 \u00een care sistemul imunitar distruge globulele ro\u0219ii. \u00cen perioadele de criz\u0103, pacien\u021bii au nevoie de imunosupresoare \u0219i transfuzii regulate. \u00cen cazul ei, terapiile standard nu mai func\u021bionau.<\/p>\n \u201ePacienta nu mai avea nicio op\u021biune terapeutic\u0103 \u0219i nu ar fi putut p\u0103r\u0103si spitalul, deoarece depindea de transfuzii zilnice\u201d, au explicat medicii.<\/p>\n Pe l\u00e2ng\u0103 AIHA, aceasta mai suferea de dou\u0103 boli autoimune<\/a>: trombocitopenie imun\u0103 (ITP), care duce la distrugerea trombocitelor \u0219i cre\u0219te riscul de s\u00e2ngerare, \u0219i sindrom antifosfolipidic (APS), care, dimpotriv\u0103, favorizeaz\u0103 formarea cheagurilor de s\u00e2nge periculoase. Toate cele trei afec\u021biuni erau cauzate de anomalii ale celulelor B, responsabile de producerea anticorpilor.<\/p>\n publicitate”); background-position: center center; background-repeat: no-repeat;”><\/p>\n Terapia care \u201ereseteaz\u0103\u201d sistemul imunitar<\/p>\n \u00cen lipsa altor solu\u021bii, medicii au propus o terapie CAR-T, folosit\u0103 deja cu succes \u00een anumite tipuri de cancer<\/a>. Procedura presupune recoltarea globulelor albe, izolarea celulelor T \u0219i modificarea lor genetic\u0103 pentru a recunoa\u0219te o protein\u0103 specific\u0103 celulelor B. Ulterior, aceste celule sunt reintroduse \u00een organism.<\/p>\n Tratamentul a ac\u021bionat rapid, distrug\u00e2nd celulele B anormale. Pacienta a avut ultima transfuzie la o s\u0103pt\u0103m\u00e2n\u0103 dup\u0103 terapie \u0219i, \u00een doar dou\u0103 s\u0103pt\u0103m\u00e2ni, era suficient de bine pentru activit\u0103\u021bi zilnice.<\/p>\n Sistemul ei imunitar a \u00eencetat s\u0103 mai atace globulele ro\u0219ii, iar celelalte afec\u021biuni autoimune s-au ameliorat. C\u00e2nd celulele B au reap\u0103rut, c\u00e2teva luni mai t\u00e2rziu, acestea p\u0103reau s\u0103n\u0103toase, suger\u00e2nd c\u0103 terapia a \u201eresetat\u201d sistemul imunitar. Detaliile sunt publicate \u00een revista Med.<\/a><\/p>\n De\u0219i pacienta prezint\u0103 \u00een continuare un num\u0103r sc\u0103zut de globule albe \u0219i valori u\u0219or crescute ale enzimelor hepatice, medicii cred c\u0103 acestea sunt consecin\u021ba tratamentelor anterioare, nu a terapiei CAR-T.<\/p>\n Speciali\u0219tii consider\u0103 cazul \u00eencurajator, dar atrag aten\u021bia c\u0103 un singur pacient nu poate demonstra eficien\u021ba general\u0103 a tratamentului. \u00cen prezent, sunt \u00een desf\u0103\u0219urare numeroase studii clinice pentru boli autoimune, inclusiv lupus \u0219i scleroz\u0103 multipl\u0103, unele oferind deja rezultate preliminare promi\u021b\u0103toare.<\/p>\n","protected":false},"excerpt":{"rendered":"O femeie care s-a confruntat timp de peste un deceniu cu trei boli autoimune grave, care \u00eei puneau…\n","protected":false},"author":2,"featured_media":155674,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[45432,32,33,31,36,37,27,74,34,35,25,41,40,38,39,26,45433,28,29,30,8955,45434,71,72,73],"class_list":{"0":"post-155673","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-international","8":"tag-boli-autoimune","9":"tag-breaking-news","10":"tag-breakingnews","11":"tag-cele-mai-populare-subiecte","12":"tag-featured-news","13":"tag-featurednews","14":"tag-headlines","15":"tag-international","16":"tag-latest-news","17":"tag-latestnews","18":"tag-news","19":"tag-ro","20":"tag-romana","21":"tag-romania","22":"tag-romanian","23":"tag-stiri","24":"tag-terapie-celulara","25":"tag-titluri","26":"tag-top-stories","27":"tag-topstories","28":"tag-tratament","29":"tag-tratament-inovator","30":"tag-world","31":"tag-world-news","32":"tag-worldnews"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ro\/116387492974539795","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/posts\/155673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/comments?post=155673"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/posts\/155673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/media\/155674"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/media?parent=155673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/categories?post=155673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ro\/wp-json\/wp\/v2\/tags?post=155673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}